Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

NK cells propagate T cell immunity following in situ tumor vaccination

Cell Reports(2023)10.1016/j.celrep.2023.113556Source: DataRank Database

NK cells propagate T cell immunity following in situ tumor vaccination is a research paper published in Cell Reports (2023). On theSindex it has a DataRank of 0. It has been cited 16 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access16 citations

Download PDF

Cite:

Linked data & code

geo refseq nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (19 grants)OA: goldTopics (32)IDs (PubMed, PMC)Annotations (3)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (16)

Justin C. Jagodinsky ORCID,Jessica M. Vera ORCID,Paul A. Clark ORCID,Cindy Zuleger ORCID,Amy K. Erbe ORCID

Live enrichment

PubMed:38096050 PMC:PMC10843551

University of Wisconsin Carbone Cancer Center

Grant: P30 CA014520

National Institutes of Health

Grant: P01CA250972

National Institutes of Health

Grant: 1DP5DO024576

National Institutes of Health

Grant: U01CA233102

National Institutes of Health

Grant: TL1TR002375

National Institutes of Health

Grant: P50 CA278595

National Institutes of Health

Grant: F30CA250263

National Institutes of Health

Grant: T32GM140935

National Institutes of Health

Grant: P50 DE026787

NIH HHS

Grant: DP5 OD024576

National Institutes of Health

Grant: 5U01CA233102-04

Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies

National Institutes of Health

Grant: 5T32GM140935-02

Integrated Training For Physician-Scientists

National Institutes of Health

Grant: 5TL1TR002375-04

NRSA Training Core

National Institutes of Health

Grant: 5F30CA250263-02

Brachytherapy to achieve in situ cancer vaccination

National Institutes of Health

Grant: 5DP5OD024576-02

Combining Radiation and Tumor-specific AntIbody Therapies to Elicit in Situ Tumor Vaccination

National Institutes of Health

Grant: 2P50CA278595-06A1

Head and Neck Cancer SPORE at the University of Wisconsin

National Institutes of Health

Grant: 5P01CA250972-02

Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response

National Institutes of Health

Grant: 5P50DE026787-02

Head and Neck Cancer SPORE at the University of Wisconsin

National Institutes of Health

Grant: 5P30CA014520-18

CANCER CENTER SUPPORT

goldLicense: cc-by

publisherhttp://www.cell.com/article/S2211124723015681/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2211124723015681?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2211124723015681?httpAccept=text/plain

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10843551/pdf/nihms-1954798.pdf

repositoryhttps://doaj.org/article/3b49ec059cc6419f9fcdd7b1869fd235

Fields of Study

03 medical and health sciences0302 clinical medicine

MeSH Terms

Killer Cells, NaturalCD8-Positive T-LymphocytesAnimalsHumansMiceMelanomaInterleukin-2Vaccination

Keywords

RadiationCTLA4IL-2NK cellT cellCD86TregTargeted Tumor TherapyIn Situ VaccinationCp: ImmunologyCp: CancerTumor-specific AntibodyQH301-705.5VaccinationCD8-Positive T-LymphocytesKiller Cells, NaturalMiceHumansAnimalsInterleukin-2Biology (General)Melanoma

Sustainable Development Goals

SDG 3: 3. Good health